Monthly HIV prevention pill put to the test – but study halted early

NCT ID NCT04652700

Terminated Prevention Sponsor: Merck Sharp & Dohme LLC Source: ClinicalTrials.gov ↗

First seen May 17, 2026 · Last updated May 25, 2026 · Updated 2 times

Summary

This study tested a once-monthly pill called islatravir to prevent HIV infection in cisgender men and transgender women who have sex with men and are at high risk. About 494 participants took either the monthly pill or an active comparator. The trial was terminated early, but researchers still looked at safety and how many people got HIV during the study.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Locations

Bridge HIV - San Francisco Department of Public Health ( Site 0003)

San Francisco, California, 94102, United States
Center Hospital of the National Center for Global Health and Medicine ( Site 0101)

Shinjyuku-ku, Tokyo, 162-8655, Japan
Central Texas Clinical Research ( Site 0002)

Austin, Texas, 78705, United States
Centro de Referência e Treinamento DST/AIDS ( Site 0351)

São Paulo, 04121-000, Brazil
Chulalongkorn University-Pediatrics ( Site 0051)

Bangkok, Bangkok, 10330, Thailand
Desmond Tutu HIV Foundation ( Site 0202)

Cape Town, Western Cape, 7925, South Africa
Global Research Institute ( Site 0031)

Los Angeles, California, 90036, United States
HIV Netherlands Australia Thailand Research Collaboration ( Site 0056)

Bangkok, Bangkok, 10330, Thailand
Howard Brown Health Center ( Site 0004)

Chicago, Illinois, 60613, United States
Hôpital Saint-Louis-Infectious Diseases and tropical diseases ( Site 0151)

Paris, Île-de-France Region, 75010, France
Midway Immunology and Research Center ( Site 0014)

Ft. Pierce, Florida, 34982, United States
Orlando Immunology Center ( Site 0010)

Orlando, Florida, 32803, United States
Perinatal HIV Research Unit (PHRU)-HIV Prevention CRS ( Site 0203)

Johannesburg, Gauteng, 1864, South Africa
Ponce De Leon Center Grady Health ( Site 0032)

Atlanta, Georgia, 30308, United States
Research Institute for Health Sciences-Research Institute for Health Sciences Building 1 ( Site 0052

Chiang Mai, 50200, Thailand
Rutgers New Jersey Medical School-Clinical Research Center ( Site 0017)

Newark, New Jersey, 07103, United States
The Crofoot Research Center ( Site 0025)

Houston, Texas, 77098, United States
The GW Medical Faculty Associates-Medicine ( Site 0033)

Washington D.C., District of Columbia, 20037, United States
The University of Mississippi Medical Center ( Site 0012)

Jackson, Mississippi, 39216, United States
The University of North Carolina at Chapel Hill ( Site 0019)

Chapel Hill, North Carolina, 27599, United States
UCLA Center for Clinical AIDS Research and Education ( Site 0011)

Los Angeles, California, 90035, United States
University of Alabama at Birmingham-UAB 1917 Research Clinic ( Site 0007)

Birmingham, Alabama, 35222, United States
University of Miami Miller School of Medicine-Infectious Disease ( Site 0029)

Miami, Florida, 33136, United States
Via Libre ( Site 0404)

Lima, 15001, Peru
Wits Reproductive Health and HIV Institute (WRHI)-Research Center ( Site 0201)

Johannesburg, Gauteng, 2000, South Africa

Conditions

Explore the condition pages connected to this study.

HIV PREEXPOSURE PROPHYLAXIS